Comment on Jiang G. et al.: Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: A meta-analysis

摘要

Dear Editor, We read with great interest the recent paper by Jiang G. et al., "Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis," published online in Tumor Biology [1]. The investigators performed a meta-analysis of five randomized controlled trials to compare the clinical efficacy and safety of temozolomide (TMZ) alone and TMZ-based combination drug therapy in patients with melanoma. It is a very interesting study. Nevertheless, we have several queries which we would like to communicate with the investigators.